-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] At 13:46 on August 17, the pharmaceutical manufacturing sector index reported 28031.
23 points, down 2%, with a turnover of 42.
610 billion yuan and a turnover rate of 1.
12%
.
Among the stocks in the sector, the five stocks with large declines were Yirui Bio, Lamei Pharmaceutical, Kanglong Chemical, Haoyuan Pharmaceutical, and Sunshine Nuohe, which fell more than 7%
.
.
Yirui Biology reported 32.
30 yuan, down 8.
83%.
According to the data, Yirui Biology is mainly engaged in the research and development, production, sales and related services of food safety accurate and rapid detection products, and has expanded into the field of in vitro diagnostic rapid detection (POCT)
.
Yirui Bio recently released the 2021 semi-annual performance forecast, and it is expected that the performance will increase in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 150 million yuan to 170 million yuan, an increase of 282.
51% to 333.
51% over the same period of the previous year
.
The company said that orders for semi-finished products of new crown antigen detection reagents and supporting solutions have increased significantly; the impact of non-recurring gains and losses on the company's net profit is about 10 million yuan, mainly government subsidies and wealth management income
.
Lai Mei Pharmaceutical reported 9.
99 yuan, down 8.
60%.
Lai Mei Pharmaceutical entered the capital market in 2009.
Its main products include anti-infective, specialty specialty (mainly including anti-tumor drugs, digestive system drugs, parenteral nutrition drugs), large Infusion, Chinese patent medicine and decoction pieces,
etc.
While concentrating resources to develop advantageous segments, the company is also actively introducing new products and technologies
.
Lai Mei Pharmaceutical said that the company plans to deploy the liver disease track, including but not limited to chronic hepatitis B, non-alcoholic fatty liver disease and other diseases
.
According to the 2020 annual report, Lai Mei Pharmaceutical is already developing a drug for intermediate and advanced liver cirrhosis-individualized anti-hepatic fibrosis macrophage injection.
It seems that it is well prepared to enter the liver disease track.
.
Kanglong Chemicals reported 185.
15 yuan, down 8.
51%.
Kanglong Chemicals provides full-process integrated drug research, development and production services from drug discovery to drug development
.
According to the main business type, it can be divided into three service modules: laboratory services, CMC (small molecule CDMO) services and clinical research services
.
The company has always attached great importance to technology and innovation.
In terms of chemical synthesis and production technology, it has continuously improved the technical standards of services by focusing on strengthening the application of high-throughput chemical reaction screening platforms, fluid chemistry technology and biological enzyme catalysis technology
.
According to the recent announcement of Kanglong Chemical, its estimated net profit in the first half of 2021 will be 498 million-594 million yuan, a year-on-year increase of 4%-24%; net profit after deducting non-recurring gains and losses is 529 million yuan-601 million yuan Yuan, a year-on-year increase of 46%-66%
.
Haoyuan Pharmaceutical reported 360.
33 yuan, down 7.
13%.
Haoyuan Pharmaceutical is an early enterprise in the development and research of ADC drugs in China.
It has strong research and development, process optimization, process verification, registration application and industrialization related to ADC medicinal chemistry.
professional ability and rich experience in project development
.
Relying on the characteristic targeted drug development platform, the company has assisted China's first application for clinical ADC class I anti-cancer drug Rongchang Bio-Weidicitumumab ( RC48) project
.
As of August 5, 2021, a total of 6 institutions have made predictions on Haoyuan Pharmaceutical's 2021 annual performance within 6 months, predicting a net profit of 196 million yuan in 2021, a year-on-year increase of 52.
26%
.
Sunshine Novo reported 91.
77 yuan, down 7.
10%.
Sunshine Novo's CRO service layout has been accelerated and improved, and a comprehensive R&D service model of "pharmaceutical research + clinical trial + biological analysis" has been formed, which can fully meet the diverse needs of customers
.
Combined with the transformation and value-added of self-developed drug technology, it will bring the competitiveness of the two-wheel drive to the company
.
At present, the company is in the growth stage, the performance continues to grow rapidly, the reserve orders are abundant, the customer base is continuously accumulated, and the long-term development is guaranteed
.
Although the company mainly focused on generic drug CRO services, it has grasped the development trend of clinical CRO for innovative drugs in the industry, and is actively expanding its clinical and operational expert teams for innovative drugs, resulting in rapid growth of related businesses
.
In terms of drug discovery and preclinical research, the company is also building a complete innovative drug service chain.
With the enrichment of innovative drug core technology platforms and the expansion of technical teams, research service capabilities have been continuously improved
.
An integrated innovative drug translational research CRO will take shape with ample growth potential
.
Analysts pointed out that although the pharmaceutical sector fluctuates in the short term, the demand for medicine is strong.
With the increase in medical demand brought about by the aging of the population and consumption upgrade, the fluctuation will not change the long-term prosperity
.
The pharmaceutical industry is expected to achieve rapid growth in the first half of 2021
.
At this time point, companies with strong performance growth certainty are worthy of attention, and it is recommended to stick to high-prosperity sub-stocks that are in line with industry development trends
.
23 points, down 2%, with a turnover of 42.
610 billion yuan and a turnover rate of 1.
12%
.
Among the stocks in the sector, the five stocks with large declines were Yirui Bio, Lamei Pharmaceutical, Kanglong Chemical, Haoyuan Pharmaceutical, and Sunshine Nuohe, which fell more than 7%
.
.
Yirui Biology reported 32.
30 yuan, down 8.
83%.
According to the data, Yirui Biology is mainly engaged in the research and development, production, sales and related services of food safety accurate and rapid detection products, and has expanded into the field of in vitro diagnostic rapid detection (POCT)
.
Yirui Bio recently released the 2021 semi-annual performance forecast, and it is expected that the performance will increase in the same direction
.
During the reporting period, the net profit attributable to shareholders of the listed company was 150 million yuan to 170 million yuan, an increase of 282.
51% to 333.
51% over the same period of the previous year
.
The company said that orders for semi-finished products of new crown antigen detection reagents and supporting solutions have increased significantly; the impact of non-recurring gains and losses on the company's net profit is about 10 million yuan, mainly government subsidies and wealth management income
.
Lai Mei Pharmaceutical reported 9.
99 yuan, down 8.
60%.
Lai Mei Pharmaceutical entered the capital market in 2009.
Its main products include anti-infective, specialty specialty (mainly including anti-tumor drugs, digestive system drugs, parenteral nutrition drugs), large Infusion, Chinese patent medicine and decoction pieces,
etc.
While concentrating resources to develop advantageous segments, the company is also actively introducing new products and technologies
.
Lai Mei Pharmaceutical said that the company plans to deploy the liver disease track, including but not limited to chronic hepatitis B, non-alcoholic fatty liver disease and other diseases
.
According to the 2020 annual report, Lai Mei Pharmaceutical is already developing a drug for intermediate and advanced liver cirrhosis-individualized anti-hepatic fibrosis macrophage injection.
It seems that it is well prepared to enter the liver disease track.
.
Kanglong Chemicals reported 185.
15 yuan, down 8.
51%.
Kanglong Chemicals provides full-process integrated drug research, development and production services from drug discovery to drug development
.
According to the main business type, it can be divided into three service modules: laboratory services, CMC (small molecule CDMO) services and clinical research services
.
The company has always attached great importance to technology and innovation.
In terms of chemical synthesis and production technology, it has continuously improved the technical standards of services by focusing on strengthening the application of high-throughput chemical reaction screening platforms, fluid chemistry technology and biological enzyme catalysis technology
.
According to the recent announcement of Kanglong Chemical, its estimated net profit in the first half of 2021 will be 498 million-594 million yuan, a year-on-year increase of 4%-24%; net profit after deducting non-recurring gains and losses is 529 million yuan-601 million yuan Yuan, a year-on-year increase of 46%-66%
.
Haoyuan Pharmaceutical reported 360.
33 yuan, down 7.
13%.
Haoyuan Pharmaceutical is an early enterprise in the development and research of ADC drugs in China.
It has strong research and development, process optimization, process verification, registration application and industrialization related to ADC medicinal chemistry.
professional ability and rich experience in project development
.
Relying on the characteristic targeted drug development platform, the company has assisted China's first application for clinical ADC class I anti-cancer drug Rongchang Bio-Weidicitumumab ( RC48) project
.
As of August 5, 2021, a total of 6 institutions have made predictions on Haoyuan Pharmaceutical's 2021 annual performance within 6 months, predicting a net profit of 196 million yuan in 2021, a year-on-year increase of 52.
26%
.
Sunshine Novo reported 91.
77 yuan, down 7.
10%.
Sunshine Novo's CRO service layout has been accelerated and improved, and a comprehensive R&D service model of "pharmaceutical research + clinical trial + biological analysis" has been formed, which can fully meet the diverse needs of customers
.
Combined with the transformation and value-added of self-developed drug technology, it will bring the competitiveness of the two-wheel drive to the company
.
At present, the company is in the growth stage, the performance continues to grow rapidly, the reserve orders are abundant, the customer base is continuously accumulated, and the long-term development is guaranteed
.
Although the company mainly focused on generic drug CRO services, it has grasped the development trend of clinical CRO for innovative drugs in the industry, and is actively expanding its clinical and operational expert teams for innovative drugs, resulting in rapid growth of related businesses
.
In terms of drug discovery and preclinical research, the company is also building a complete innovative drug service chain.
With the enrichment of innovative drug core technology platforms and the expansion of technical teams, research service capabilities have been continuously improved
.
An integrated innovative drug translational research CRO will take shape with ample growth potential
.
Analysts pointed out that although the pharmaceutical sector fluctuates in the short term, the demand for medicine is strong.
With the increase in medical demand brought about by the aging of the population and consumption upgrade, the fluctuation will not change the long-term prosperity
.
The pharmaceutical industry is expected to achieve rapid growth in the first half of 2021
.
At this time point, companies with strong performance growth certainty are worthy of attention, and it is recommended to stick to high-prosperity sub-stocks that are in line with industry development trends
.
